Answers are grounded in this paper and cite their sources.
From its earliest conception, gene therapy held the promise of correcting inherited diseases by inserting a normal copy of the relevant gene into somatic cells.1 Common monogenic diseases of blood cells, such as sickle cell disease or β-thalassemia, were originally considered important candidates for gene therapy because they were well understood at the molecular level and because the target cell, the hematopoietic stem cell, is easily accessible and can be explanted, genetically corrected in the laboratory, and then retransplanted.2 The advantage of gene therapy over the conventional transplantation of hematopoietic stem cells from compatible donors is that gene therapy is . . .
No takes yet. Share an insight, caveat, or question.
Kohn et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: